Viracta Therapeutics News

Viracta Therapeutics Analyst Ratings

BenzingaAug 15 22:57

RBC Adjusts Price Target on Viracta Therapeutics to $4 From $6, Maintains Outperform

MT NewswiresAug 15 20:47

Viracta Therapeutics Analyst Ratings

BenzingaMay 23 20:25

Viracta Therapeutics Inc: Oppenheimer cuts price target from $13 to $11

Zhitong FinanceMay 23 20:18

Oppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)

TipRanksMay 23 19:55

RBC Capital Keeps Their Buy Rating on Viracta Therapeutics (VIRX)

TipRanksMay 10 19:01

Oppenheimer: Maintaining the Viracta Therapeutics (VIRX.US) rating, adjusted from being superior to better than the market rating, with a target price of $13.00.

Zhitong FinanceApr 17 20:50

Viracta Therapeutics Analyst Ratings

BenzingaApr 17 20:50

Oppenheimer Maintains Outperform on Viracta Therapeutics, Maintains $13 Price Target

BenzingaApr 17 20:50

Analysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)

TipRanksApr 17 19:55

Viracta Therapeutics Analyst Ratings

BenzingaApr 16 22:45

HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $4 Price Target

BenzingaApr 16 22:45

Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)

TipRanksApr 16 18:35

Buy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financials

TipRanksMar 12 18:30

Viracta Therapeutics Analyst Ratings

BenzingaMar 12 18:20

HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $4 Price Target

BenzingaMar 12 18:20

Analysts Are Bullish on These Healthcare Stocks: ITeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)

TipRanksMar 11 12:55

RBC Capital Sticks to Its Buy Rating for Viracta Therapeutics (VIRX)

TipRanksMar 8 20:31

HC Wainwright & Co. Maintains Buy on Viracta Therapeutics, Lowers Price Target to $4

BenzingaJan 5 19:17

Viracta Therapeutics Analyst Ratings

BenzingaJan 5 19:17